Shopping Cart
- Remove All
- Your shopping cart is currently empty
LD2 is a protein arginine methyltransferase 9 (PRMT9; IC50 = 0.9 µM) inhibitor. It can reduce the proliferation ability of Rec-1 and Raji lymphoblast cells, UPN1 mantle cell lymphoma, BL-41 Burkitt lymphoma, and OCI-Ly3 diffuse large B-cell lymphoma (DLBCL) cells (IC50s = 2.5-5 µM). LD2 (2.5 µM) can induce G2/M phase cell cycle arrest in THP-1 acute myeloid leukemia (AML) cells and reduce the phosphorylation levels of checkpoint kinases 1 (Chk1) and Chk2 in their cells.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | LD2 is a protein arginine methyltransferase 9 (PRMT9; IC50 = 0.9 µM) inhibitor. It can reduce the proliferation ability of Rec-1 and Raji lymphoblast cells, UPN1 mantle cell lymphoma, BL-41 Burkitt lymphoma, and OCI-Ly3 diffuse large B-cell lymphoma (DLBCL) cells (IC50s = 2.5-5 µM). LD2 (2.5 µM) can induce G2/M phase cell cycle arrest in THP-1 acute myeloid leukemia (AML) cells and reduce the phosphorylation levels of checkpoint kinases 1 (Chk1) and Chk2 in their cells. |
Molecular Weight | 247.68 |
Formula | C12H10ClN3O |
Cas No. | 1134334-55-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.